Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498515 | 0.90 | HSD17B10 (0.63) | HSD17B10BRD4POLBALDH1A1HPGD | |
| SCHEMBL28804225 | 0.85 | ALDH1A1 (0.46) | HSD17B10ALDH1A1THRATHRBLMNA | |
| SCHEMBL9287644 | 0.83 | HSD17B10 (0.68) | HSD17B10BRD4POLBALDH1A1HPGD | |
| SCHEMBL19389323 | 0.82 | HSD17B10 (0.52) | HSD17B10BRD4POLBALDH1A1HPGD | |
| SCHEMBL8886874 | 0.81 | HSD17B10 (0.66) | HSD17B10BRD4POLBALDH1A1HPGD | |
| SCHEMBL25414139 | 0.81 | TDP2 (0.42) | HSD17B10POLBTHRATHRBLMNA | |
| SCHEMBL28422486 | 0.81 | KMT2A (0.43) | HSD17B10BRD4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30557302 | 0.80 | KMT2A (0.50) | POLBALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL9244529 | 0.80 | TGM2 (0.47) | POLBALDH1A1HPGDTHRATHRB | |
| SCHEMBL11765981 | 0.80 | BRD4 (0.45) | HSD17B10BRD4POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114794-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| CN-111918881-B | Novel photocrosslinkable alginic acid derivative | 持田制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| EP-3865494-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-111918881-A | Novel photocrosslinkable alginic acid derivative | 持田制药株式会社 | 2020-11-10 | — | — | CN | disclosed |
| EP-1567535-B1 | BIDENTATE C,P CHIRAL PHOSPHINE LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6984744-B2 | Phosphine ligands | HOFFMAN-LA ROCHE INC. (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1567535-A1 | BIDENTATE C,P CHIRAL PHOSPHINE LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050669-A1 | BIDENTATE C,P CHIRAL PHOSPHINE LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110975-A1 | 2-(2-phosphinoethyl)phospholanes and transition metal complexes with such ligands in asymmetric hydrogenation reactions; phospholone intermediates | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | US | disclosed |
| CN-1067071-C | Carboline derivatives | ICOS CORP (US) | 2001-06-13 | — | — | CN | disclosed |
| CN-1218471-A | Carboline derivatives | ICOS CORP (US) | 1999-06-02 | — | — | CN | disclosed |
| US-4087598-A | Mercurated polymers, method for their preparation and polymers produced therefrom | CESKOSLOVENSKA AKADEMIE VED (CS) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110975-A1 | 2-(2-phosphinoethyl)phospholanes and transition metal complexes with such ligands in asymmetric hydrogenation reactions; phospholone intermediates | CCRL2, LUC7L2, CDKL1 | HSD17B10 1232/4885BRD4 3602/4885POLB 2673/4885 |
| US-20230114794-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | AP2M1, AP3M1, AP1M1 | HSD17B10 1478/4885BRD4 2287/4885POLB 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.